Celecoxib Benefits Not Seen in Acute Renal Colic Patients
Patients with ureteral stones had similar stone passage, pain whether taking drug or placebo
WEDNESDAY, Dec. 9 (HealthDay News) -- In patients with ureteral stones and acute renal colic, the use of celecoxib was not associated with time until stone passage or decreased pain, according to research published in the November issue of Urology.
Elizabeth Phillips, M.D., of the University of Minnesota in Minneapolis, and colleagues analyzed data from 53 patients who presented to an emergency department with ureteral stones less than 10 millimeters in diameter. Patients were randomized to receive celecoxib for 10 days, with an initial dose of 400 milligrams, or placebo. Patients did not require hospital admission, and they were also prescribed hydrocodone or other narcotic.
The researchers found that the groups had similar rates of spontaneous stone passage (55.2 percent for celecoxib versus 54.2 percent for placebo), similar days to stone passage, and similar size of stone passed. The groups also had similar pain analog scores and narcotic usage.
"It is difficult to resolve the discrepancy between in vitro studies demonstrating ureteral relaxation and decrease in intrarenal pelvic pressures and the lack of a clinical response in our study with regard to an absence of effect on renal colic. As such, we recommend the use of narcotics in combination with ketorolac for analgesic relief and alpha-blockers for medical expulsive therapy, without the concomitant administration of a COX-2 inhibitor," the authors conclude.
The study was funded by Pfizer Pharmaceuticals.